Therapeutics + Diagnostics = Theranostics
In the ever-evolving field of nuclear medicine, Theranostic care is emerging as a groundbreaking approach, offering new hope for cancer patients worldwide. Theranostic care combines therapeutic and diagnostic capabilities into a single treatment, allowing for more precise and effective cancer management.
Understanding theranostic care
Theranostic care combines therapeutic and diagnostic capabilities into a single treatment, which allows for more precise and effective cancer management. This innovative approach utilizes radioactive isotopes or radiotracers to target and treat cancer cells.
The idea of this treatment is to harness the power of radioactivity which can kill the cancer cell without affecting the healthy cell.
How do radiotracers work in theranostic
Theranostic radiotracers are like little guided missiles for cancer treatment and diagnosis. They have two main parts. One part, the biological side, travels through bloodstream to latch onto a specific target, usually a type of cancer cell. The other part is radioactive.
When we’re diagnosing, the radioactive part emits a tiny bit of radiation, which helps us take pictures of the cancer cells the radiotracer has found. For treatment, the biological side remains almost the same, but the radioactive part is swapped for a stronger radiation that can actually kill the cancer cells.
What’s neat is that during both diagnosis and treatment, the biological side sticks to that specific target on the tumor cells. Most healthy cells don’t have this target, so the radiotracers just ignore them, making the whole process more precise and less harmful to the rest of the body.
What types of cancer can be treated with theranostics?
Theranostics isn’t new type of treatment, in fact year 2021 marks the 80th anniversary of the very first theragnostic agent, radioactive Iodine which is used for the treatment of thyroid cancer till today.
In modern theranostics, Lu177 was first used in 2015, and Ac225 was used in the latter part of 2016. Today, almost any type of cancer can be treated with theranostics, depending on identifying a good target in the cancer cells
Thyroid Cancer
Thyroid cancer arises from the thyroid gland & The most common types are papillary and follicular thyroid cancers, which generally have a good prognosis when treated effectively.
I-131 is the primary radioisotopes for the theranostic care for treating thyroid cancer due to its shorter half life comapre to I-123 or I-124.
The theranostic approach in thyroid cancer treatment allows for a highly personalized treatment plan.
Prostate Cancer
For the theranostic treatment of prostate cancer, parimay target is the Prostate-Specific Membrane Antigen (PSMA)
177Lu-PSMA (Lutetium-177 labeled PSMA) is widely used for both diagnostic imaging (PET) and therapy of METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (mCRPC).
225Ac-PSMA (Actinium-225 labeled PSMA) is used primarily for therapeutic purposes in advanced prostate cancer.
Ac225 is used for treating advanced mCRPC, particularly in patients who have not responded to other treatments.
Neuroendocrine Cancer
Specific radioisotopes are employed to diagnose and treat the disease effectively for the theranostic treatment of neuroendocrine tumors (NETs)
68Ga-DOTATATE and 68Ga-DOTATOC are used primarily for PET imaging in neuroendocrine tumors. It emits positrons, which are used in PET scans to locate and assess the extent of neuroendocrine tumors and evaluate the efficacy of treatment.
177Lu-DOTATATE (Lutetium-177 labeled DOTATATE) is a key radioisotope used for treating and imaging neuroendocrine tumors.
MED I Thailand: Your Partner in Advanced Cancer Care
Theranostic care is a treasured tailor in future oncology. At MED I Thailand, we are dedicated to advancing cancer treatment through innovative theranostic solutions. Our first step is to deliver the Lutetium Chloride solution for radiolabeling, which is a critical component of Lutetium PSMA therapy.
We are committed to expanding our offerings with the future availability of AC225. Our capabilities extend beyond these radioisotopes to providing various isotopes required by oncologists for both treatment and research purposes.
By partnering with us, healthcare providers can access required radioisotopes, ensuring the availability of this life-saving therapy to patients in need. Our commitment to excellence and patient-centered care drives us to improve and expand our offerings continuously.
Connect with Us
Don’t hesitate to get in touch with any query about theranostic solutions. We have highly experienced team to answer your query. Or drop a message to meet with us over a cup of coffee.